Free Newsletter
Lilly prices new clot-buster at 31% premium
Free newsletter via e-mail
Tools
Eli Lilly launched its new blood thinner in its first market today: the U.K. Effient/Efient (prasugrel) is priced 31 percent higher than its rival Plavix, the world's leading anticoagulant marketed by Bristol-Myers Squibb and Sanofi Aventis. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: